Peer-influenced content. Sources you trust. No registration required. This is HCN.
MD Newsline
A patient with advanced follicular lymphoma described a prolonged diagnostic journey marked by evolving symptoms, initial alternative diagnoses, urgent treatment initiation, and the psychological challenges that continued long after active therapy began.
Hematology October 12th 2026
Pediatric Blood & Cancer
In a French retrospective cohort, infants with Ewing sarcoma had favorable long-term survival after age-adjusted chemotherapy and predominantly surgical local control, although the 17-patient sample limits conclusions about treatment intensity and late toxicity.
Medical Oncology October 8th 2026
American Nurse Journal (ANJ)
Breast cancer remains the most prevalent cancer among U.S. women, with diagnoses and mortality projected to rise over the next two decades. Nurses play a central role in early recognition, patient education, treatment support, and ongoing surveillance throughout the care continuum.
Community/Public Health Nursing October 7th 2026
Cancer Therapy Advisor
ASCO released updated recommendations for recurrent ovarian cancer that reinforce platinum-based doublet therapy as the preferred approach for platinum-sensitive disease and provide guidance for platinum-resistant disease, maintenance strategies, and monitoring. Recommendations were derived from a systematic review of studies published through 2025.
Gynecologic Oncology July 29th 2026
Rare Disease Advisor
A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.
Hematology/Oncology June 22nd 2026
In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.